SG11201911543UA - Synthesis of substantially diastereomerically pure phosphate protides - Google Patents

Synthesis of substantially diastereomerically pure phosphate protides

Info

Publication number: SG11201911543UA
Authority: SG; Singapore
Prior art keywords: protides; synthesis; diastereomerically pure; substantially diastereomerically; pure phosphate
Prior art date: 2017-06-14

Application number

SG11201911543UA

Inventor

Hugh Griffith

Gordon Kennovin

Venkata Lakshmi Narasimha Rao Dammalapati

Mani Bushan Kotala

Original Assignee

NuCana plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-14

Filing date

2018-06-14

Publication date

2020-01-30

2018-06-14 Application filed by NuCana plc filed Critical NuCana plc

2020-01-30 Publication of SG11201911543UA publication Critical patent/SG11201911543UA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SG11201911543UA 2017-06-14 2018-06-14 Synthesis of substantially diastereomerically pure phosphate protides SG11201911543UA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1709471.5A GB201709471D0 (en)	2017-06-14	2017-06-14	Diastereoselective synthesis of hosphate derivatives
PCT/GB2018/051638 WO2018229493A2 (en)	2017-06-14	2018-06-14	Synthesis of phosphate derivatives

Publications (1)

Publication Number	Publication Date
SG11201911543UA true SG11201911543UA (en)	2020-01-30

Family

ID=59358400

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201911543UA SG11201911543UA (en)	2017-06-14	2018-06-14	Synthesis of substantially diastereomerically pure phosphate protides

Country Status (17)

Country	Link
US (3)	US11414452B2 (en)
EP (2)	EP3638685A1 (en)
JP (4)	JP7279991B2 (en)
KR (2)	KR102695300B1 (en)
CN (3)	CN110785425B (en)
AU (3)	AU2018284131B2 (en)
BR (1)	BR112019026747A2 (en)
CA (2)	CA3065682A1 (en)
CL (1)	CL2019003632A1 (en)
EA (1)	EA201992873A1 (en)
GB (1)	GB201709471D0 (en)
IL (3)	IL302559B2 (en)
MA (1)	MA49379A (en)
MX (3)	MX2019014907A (en)
SA (1)	SA519410795B1 (en)
SG (1)	SG11201911543UA (en)
WO (2)	WO2018229493A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2681227B1 (en)	2011-03-01	2016-02-10	Nucana Biomed Limited	Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
BR112016025787B1 (en)	2014-06-25	2022-12-13	NuCana plc	PHARMACEUTICAL FORMULATION COMPRISING GENCITABIN-[PHENYL-(BENZOXY-L-ALANINYL)]-PHOSPHATE, ITS USE IN THE TREATMENT OF CANCER, METHOD OF PREPARATION AND KIT COMPRISING THE SAME
KR20230098915A (en) *	2014-11-28	2023-07-04	뉴카나 피엘씨	New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
CN115746073A (en)	2015-12-11	2023-03-07	努卡那有限公司	Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031
GB201522764D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Formulations of phosphate derivatives
GB201609600D0 (en)	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Cancer treatments
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en)	2017-09-18	2017-11-01	Nucana Biomed Ltd	Floxuridine synthesis
CN112409421A (en) *	2020-12-01	2021-02-26	上海兆维科技发展有限公司	Preparation method of 3' -phosphate nucleoside
WO2023218202A2 (en)	2022-05-12	2023-11-16	NuCana plc	Cancer treatment
WO2024121527A1 (en)	2022-12-07	2024-06-13	NuCana plc	Synthesis of nucleoside derivative nuc-3373

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE279248C (en)
US3792039A (en)	1971-12-27	1974-02-12	Miles Lab	Poly 2'-fluoro-2'-deoxyuridylic acid
US4500707A (en) *	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US4357324A (en)	1981-02-24	1982-11-02	The United States Of America As Represented By The Department Of Health And Human Services	Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4668777A (en) *	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
US6339151B1 (en)	1998-01-23	2002-01-15	Newbiotics, Inc.	Enzyme catalyzed therapeutic agents
US6683061B1 (en)	1999-07-22	2004-01-27	Newbiotics, Inc.	Enzyme catalyzed therapeutic activation
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
US8399428B2 (en)	2004-12-09	2013-03-19	Regents Of The University Of Minnesota	Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
CA2618335C (en)	2005-08-15	2015-03-31	F.Hoffmann-La Roche Ag	Antiviral phosphoramidates of 4'-substituted pronucleotides
GB0623493D0 (en)	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
US7951789B2 (en) *	2006-12-28	2011-05-31	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US20090206007A1 (en)	2008-02-20	2009-08-20	Air Products And Chemicals, Inc.	Process and apparatus for upgrading coal using supercritical water
MX2011007364A (en)	2009-01-09	2012-02-28	Univ Cardiff	Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections.
US20100249068A1 (en)	2009-03-20	2010-09-30	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
TWI576352B (en)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	Nucleoside phosphoramidates
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
UA122959C2 (en)	2010-03-31	2021-01-27	Гайлід Фармассет Елелсі	NUCLEOSIDE PHOSPHORAMIDATES
EP3290428B1 (en)	2010-03-31	2021-10-13	Gilead Pharmasset LLC	Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
EA025311B1 (en)	2010-07-19	2016-12-30	Гайлид Сайэнсиз, Инк.	Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
EP2619216A4 (en)	2010-09-22	2014-04-02	Alios Biopharma Inc	Substituted nucleotide analogs
WO2012040126A1 (en)	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
JP6069215B2 (en)	2010-11-30	2017-02-01	ギリアドファーマセットエルエルシー	Compound
CA2819041A1 (en)	2010-12-22	2012-06-28	Alios Biopharma, Inc.	Cyclic nucleotide analogs
EP2681227B1 (en)	2011-03-01	2016-02-10	Nucana Biomed Limited	Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
ES2671478T3 (en)	2012-08-31	2018-06-06	Novartis Ag	2'-ethinyl nucleoside derivatives for the treatment of viral infections
KR20150103669A (en)	2012-11-16	2015-09-11	유니버시티 칼리지 카디프 컨설턴트 리미티드	Process for preparing nucleoside prodrugs
TW201542578A (en)	2013-06-26	2015-11-16	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
JP6762873B2 (en)	2013-09-11	2020-09-30	エモリー・ユニバーシテイ	Nucleotide and nucleoside compositions and related uses
SG11201602595TA (en)	2013-10-11	2016-04-28	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
RU2016125213A (en)	2013-11-27	2017-12-29	АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи	NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER
CZ307789B6 (en) *	2014-04-15	2019-05-09	Zentiva, K.S.	Method of producing biologically active phosphoramidate medicaments
EP3131914B1 (en)	2014-04-16	2023-05-10	Idenix Pharmaceuticals LLC	3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
BR112016025787B1 (en)	2014-06-25	2022-12-13	NuCana plc	PHARMACEUTICAL FORMULATION COMPRISING GENCITABIN-[PHENYL-(BENZOXY-L-ALANINYL)]-PHOSPHATE, ITS USE IN THE TREATMENT OF CANCER, METHOD OF PREPARATION AND KIT COMPRISING THE SAME
MX2021001140A (en)	2014-06-25	2022-04-21	Nucana Biomed Ltd	Gemcitabine prodrugs.
US9834577B2 (en)	2014-07-22	2017-12-05	Laurus Labs Limited	Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
PT3572410T (en) *	2014-08-25	2022-09-15	Medivir Ab	Dioxolane analogues of uridine for the treatment of cancer
GB201417644D0 (en)	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
CN105646629A (en)	2014-11-25	2016-06-08	广州市恒诺康医药科技有限公司	L-nucleoside compounds and application thereof
KR20230098915A (en) *	2014-11-28	2023-07-04	뉴카나 피엘씨	New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
WO2016098123A2 (en) *	2014-12-16	2016-06-23	Laurus Labs Private Ltd	A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers
WO2016145142A1 (en)	2015-03-10	2016-09-15	Emory University	Nucleotide and nucleoside therapeutics compositions and uses related thereto
HUE038541T2 (en)	2015-05-14	2018-10-29	NuCana plc	Cancer treatments
CN106539810B (en)	2015-09-16	2021-03-09	济南高合医疗科技有限公司	Composition enriched in NUC-1031 single isomer, and preparation method and application thereof
CN106543220A (en)	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	Phosphoramidate compounds and preparation method thereof and crystal
CN106543252A (en)	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	The Preparation Method And Their Intermediate of nucleoside phosphoramidate class prodrug
KR20180063075A (en)	2015-10-05	2018-06-11	뉴카나 피엘씨	Combination therapy
CA3005444A1 (en) *	2015-11-16	2017-05-26	Ichorion Therapeutics, Inc.	Nucleic acid prodrugs
CN115746073A (en)	2015-12-11	2023-03-07	努卡那有限公司	Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031
US20190022117A1 (en)	2015-12-23	2019-01-24	NuCana plc	Combination therapy
GB201522764D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Formulations of phosphate derivatives
GB201609602D0 (en)	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Chemical compounds
GB201609601D0 (en)	2016-06-01	2016-07-13	Nucana Biomed Ltd	Phosphoramidate compounds
GB201609600D0 (en)	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Cancer treatments
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en)	2017-08-30	2017-10-11	Nucana Biomed Ltd	Treatment regimens

2017
- 2017-06-14 GB GBGB1709471.5A patent/GB201709471D0/en not_active Ceased
2018
- 2018-06-14 JP JP2019569286A patent/JP7279991B2/en active Active
- 2018-06-14 EP EP18735381.8A patent/EP3638685A1/en active Pending
- 2018-06-14 US US16/623,263 patent/US11414452B2/en active Active
- 2018-06-14 MA MA049379A patent/MA49379A/en unknown
- 2018-06-14 AU AU2018284131A patent/AU2018284131B2/en active Active
- 2018-06-14 CA CA3065682A patent/CA3065682A1/en active Pending
- 2018-06-14 KR KR1020197036989A patent/KR102695300B1/en active IP Right Grant
- 2018-06-14 CN CN201880039189.1A patent/CN110785425B/en active Active
- 2018-06-14 MX MX2019014907A patent/MX2019014907A/en unknown
- 2018-06-14 JP JP2019569336A patent/JP7248209B2/en active Active
- 2018-06-14 CA CA3064177A patent/CA3064177A1/en active Pending
- 2018-06-14 IL IL302559A patent/IL302559B2/en unknown
- 2018-06-14 MX MX2019014914A patent/MX2019014914A/en unknown
- 2018-06-14 BR BR112019026747-6A patent/BR112019026747A2/en unknown
- 2018-06-14 EA EA201992873A patent/EA201992873A1/en unknown
- 2018-06-14 WO PCT/GB2018/051638 patent/WO2018229493A2/en active Application Filing
- 2018-06-14 KR KR1020247026745A patent/KR20240127483A/en active Application Filing
- 2018-06-14 EP EP18735380.0A patent/EP3638684A2/en active Pending
- 2018-06-14 US US16/623,272 patent/US11897913B2/en active Active
- 2018-06-14 IL IL271159A patent/IL271159B2/en unknown
- 2018-06-14 SG SG11201911543UA patent/SG11201911543UA/en unknown
- 2018-06-14 CN CN201880039747.4A patent/CN110753697B/en active Active
- 2018-06-14 IL IL312228A patent/IL312228A/en unknown
- 2018-06-14 CN CN202311430904.3A patent/CN117486959A/en active Pending
- 2018-06-14 WO PCT/GB2018/051641 patent/WO2018229495A1/en unknown
2019
- 2019-12-10 MX MX2022003822A patent/MX2022003822A/en unknown
- 2019-12-11 CL CL2019003632A patent/CL2019003632A1/en unknown
- 2019-12-12 SA SA519410795A patent/SA519410795B1/en unknown
2022
- 2022-06-30 AU AU2022204691A patent/AU2022204691B2/en active Active
- 2022-08-15 US US17/888,312 patent/US12054511B2/en active Active
2023
- 2023-05-02 JP JP2023076006A patent/JP7525687B2/en active Active
2024
- 2024-01-24 AU AU2024200428A patent/AU2024200428A1/en active Pending
- 2024-07-18 JP JP2024114519A patent/JP2024138523A/en active Pending

Also Published As

Publication number	Publication date
WO2018229495A1 (en)	2018-12-20
CN110785425A (en)	2020-02-11
SA519410795B1 (en)	2023-11-19
CN117486959A (en)	2024-02-02
MX2019014907A (en)	2020-02-13
KR102695300B1 (en)	2024-08-16
JP7279991B2 (en)	2023-05-23
MA49379A (en)	2020-04-22
IL302559A (en)	2023-07-01
WO2018229493A2 (en)	2018-12-20
WO2018229493A3 (en)	2019-02-07
AU2022204691B2 (en)	2023-11-23
CL2019003632A1 (en)	2020-08-14
MX2022003822A (en)	2022-05-25
JP7525687B2 (en)	2024-07-30
US20200181186A1 (en)	2020-06-11
KR20240127483A (en)	2024-08-22
KR20200016864A (en)	2020-02-17
IL302559B1 (en)	2024-05-01
GB201709471D0 (en)	2017-07-26
IL271159B2 (en)	2023-10-01
US11414452B2 (en)	2022-08-16
US12054511B2 (en)	2024-08-06
BR112019026747A2 (en)	2020-06-30
JP2020523381A (en)	2020-08-06
US20200181190A1 (en)	2020-06-11
MX2019014914A (en)	2020-02-13
JP2024138523A (en)	2024-10-08
EA201992873A1 (en)	2020-05-19
US20220402962A1 (en)	2022-12-22
CN110753697B (en)	2023-10-13
CA3065682A1 (en)	2018-12-20
IL271159B1 (en)	2023-06-01
JP2020523378A (en)	2020-08-06
IL302559B2 (en)	2024-09-01
CA3064177A1 (en)	2018-12-20
JP7248209B2 (en)	2023-03-29
EP3638685A1 (en)	2020-04-22
IL271159A (en)	2020-01-30
US11897913B2 (en)	2024-02-13
CN110785425B (en)	2023-11-21
AU2018284131A1 (en)	2020-01-16
AU2022204691A1 (en)	2022-08-04
IL312228A (en)	2024-06-01
JP2023095954A (en)	2023-07-06
EP3638684A2 (en)	2020-04-22
AU2024200428A1 (en)	2024-02-08
AU2018284131B2 (en)	2022-04-07
CN110753697A (en)	2020-02-04

Publication	Publication Date	Title
IL271159A (en)	2020-01-30	Synthesis of substantially diastereomerically pure phosphate protides
EP3394698A4 (en)	2019-07-24	Computational localization of fibrillation sources
PL3261044T3 (en)	2021-10-04	System for customized manufacture of wearable or medical products
SG10202111790YA (en)	2021-12-30	Synthesis of omecamtiv mecarbil
PL3577125T3 (en)	2024-09-16	Crystalline forms of tenofovir alafenamide
EP3500286A4 (en)	2020-03-25	N-carboxyanhydride-based-scale synthesis of elamipretide
GB201517844D0 (en)	2015-11-25	Binaural synthesis
HK1250719A1 (en)	2019-01-11	Synthesis of desosamines
HUE066451T2 (en)	2024-08-28	Synthesis of mesotrione
EP3573650A4 (en)	2020-12-09	Diagnosis of scleroderma
IL248283B (en)	2019-01-31	Method for the synthesis of clofarabine
IL250846A0 (en)	2017-04-30	Synthesis of cyclocreatine and analogs thereof
HK1245015A1 (en)	2018-08-24	Synthesis of cyclocreatine and analogs thereof
GB2574946B (en)	2020-04-22	Binaural synthesis
PT3713939T (en)	2021-09-16	Improved process for the synthesis of linker-drug vc-seco
GB201807468D0 (en)	2018-06-20	Methods of synthesis
PT3320102T (en)	2019-12-06	Method for the synthesis of pentostatin
GB201611620D0 (en)	2016-08-17	Novel formulations of valsartan
GB201611600D0 (en)	2016-08-17	Novel formulations of valsartan
GB201402645D0 (en)	2014-04-02	Moisturising body lotion for the treatment of the visible symptoms of Keratosis Pilaris